Carna Biosciences, Inc. (TYO:4572)

Carna Biosciences Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-	-2,173	-1,130	-1,323	-532	-1,102
Depreciation & Amortization	-	31	35	33	19	12
Loss (Gain) From Sale of Assets	-	93	4	44	9	26
Other Operating Activities	-	-18	-35	-16	49	-135
Change in Accounts Receivable	-	704	-599	1,069	-1,110	-13
Change in Inventory	-	-14	-21	-8	-5	-5
Change in Accounts Payable	-	-38	-44	-73	-20	70
Change in Other Net Operating Assets	-	41	113	-434	54	-113
Operating Cash Flow	-	-1,374	-1,677	-708	-1,536	-1,260
Capital Expenditures	-	-13	-11	-126	-41	-64
Sale (Purchase) of Intangibles	-	-	-	-	-	-4
Other Investing Activities	-	-	-	1	-	-2
Investing Cash Flow	-	-13	-11	-125	-41	-70
Long-Term Debt Issued	-	-	-	-	300	-
Long-Term Debt Repaid	-	-120	-151	-239	-190	-298
Net Debt Issued (Repaid)	-	-120	-151	-239	110	-298
Issuance of Common Stock	-	694	1,343	606	957	1,023
Other Financing Activities	-	-7	-10	-	-3	-1
Financing Cash Flow	-	567	1,182	367	1,064	724
Foreign Exchange Rate Adjustments	-	39	16	28	31	-8
Miscellaneous Cash Flow Adjustments	-	1	1	-	1	-1
Net Cash Flow	-	-780	-489	-438	-481	-615
Free Cash Flow	-	-1,387	-1,688	-834	-1,577	-1,324
Free Cash Flow Margin	-	-218.08%	-103.88%	-60.17%	-78.19%	-116.86%
Free Cash Flow Per Share	-	-77.44	-100.48	-61.24	-124.22	-107.65
Cash Interest Paid	-	2	3	5	4	7
Cash Income Tax Paid	-	18	33	18	-40	135
Levered Free Cash Flow	-	-662.38	-1,290	-364.5	-1,451	-990
Unlevered Free Cash Flow	-	-660.5	-1,287	-360.75	-1,449	-985.63
Change in Net Working Capital	60.03	-619	613	-526	1,095	269

Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.